<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174718</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0766</org_study_id>
    <nct_id>NCT02174718</nct_id>
  </id_info>
  <brief_title>Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME</brief_title>
  <acronym>D3forME</acronym>
  <official_title>Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical need exists for non-oral vitamin D administration. This study is designed to test&#xD;
      a new proprietary transdermal system. It is looking to see if this new system will safely and&#xD;
      successfully deliver vitamin D3 to humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be conducted in 3 stages. The hypotheses of this work are as follows:&#xD;
&#xD;
        1. The D3forME topical supplement patch will effectively and safely raise serum 25(OH)D3 in&#xD;
           humans.&#xD;
&#xD;
        2. The 25(OH)D3 increment with a daily 4,000 IU D3forME topical supplement patch will be&#xD;
           superior to a placebo patch.&#xD;
&#xD;
        3. The 25(OH)D3 increment with a daily 4,000 IU D3forME topical supplement patch will be&#xD;
           non-inferior to that achieved with 4,000 IU of oral vitamin D3 daily.&#xD;
&#xD;
        4. The 25(OH)D3 increase achieved with the D3forME topical supplement patch will not differ&#xD;
           between young and older adults.&#xD;
&#xD;
      To test these hypotheses, this research will be conducted in three stages:&#xD;
&#xD;
      Stage 1: Open Label Proof of Concept Pilot Study. This study will document safety and&#xD;
      tolerability of daily D3forME topical supplement patches containing 4,000 IU of vitamin D3 in&#xD;
      15 healthy adult men and women.&#xD;
&#xD;
      The specific aims of this study are to:&#xD;
&#xD;
        1. Document the change in serum 25(OH)D3 with daily transdermal vitamin D3 dosing of 4,000&#xD;
           IU using the D3forME topical supplement patch.&#xD;
&#xD;
        2. Evaluate safety and skin tolerability of the D3forME topical supplement patch.&#xD;
&#xD;
      Stage 2: Efficacy study. In this randomized, double blind placebo controlled study of four&#xD;
      months duration involving 40 healthy adult men and women (n = 20 per group) the specific aims&#xD;
      are to:&#xD;
&#xD;
        1. Evaluate the safety and efficacy of daily D3forME topical supplement patches to increase&#xD;
           serum 25(OH)D3.&#xD;
&#xD;
        2. Determine if the 25(OH)D3 increase achieved by 4,000 IU of daily D3forME topical&#xD;
           supplement patches is superior to placebo.&#xD;
&#xD;
      Stage 3: Non-inferiority study. In this randomized, double blind placebo controlled study of&#xD;
      six months duration involving 220 healthy adult men and women in two age cohorts, (18-40&#xD;
      years and 65-85 years), the specific aims are to:&#xD;
&#xD;
        1. Determine if the 25(OH)D3 increase achieved by 4,000 IU of daily D3forME topical&#xD;
           supplement patches is not inferior to that achieved by 4,000 IU oral vitamin D3&#xD;
           supplementation.&#xD;
&#xD;
        2. Assess if the 25(OH)D3 increase achieved by daily D3forME topical supplement patches&#xD;
           differs between young and old adults.&#xD;
&#xD;
      As an exploratory endpoint, the potential effect of body fat on response to daily D3forME&#xD;
      topical supplement patches will be evaluated using DXA to measure body composition in the&#xD;
      efficacy and non-inferiority studies (stages 2 and 3 above).&#xD;
&#xD;
      Open-label Proof of Concept Pilot Study. This open label study will evaluate the safety of a&#xD;
      once daily D3forME topical supplement patches containing 4,000 IU of vitamin D3.&#xD;
      Additionally, it will begin evaluating the efficacy of this approach on serum 25(OH)D3. This&#xD;
      pilot study will include 15 healthy community dwelling men and women age 18-75 years without&#xD;
      conditions contraindicating D supplementation or known skin conditions that could potentially&#xD;
      interfere with cutaneous vitamin D3 delivery. Volunteers will be recruited from the Madison,&#xD;
      WI area.&#xD;
&#xD;
      Stage 2: Randomized Double-blind, Placebo Controlled Efficacy Study: This study will include&#xD;
      40 adults (n = 20 in each group) using the same inclusion/exclusion criteria&#xD;
&#xD;
      Stage 3: Non-inferiority Study: This phase will include 220 adults randomly assigned to one&#xD;
      of three treatment arms: n = 100 transdermal patch/placebo oral, n = 100 oral&#xD;
      supplementation/placebo patch and n = 20 placebo oral and placebo patch) using the same&#xD;
      inclusion/exclusion criteria as the noted above, except for age, which will be limited to&#xD;
      18-40 and 65-85. Additionally, each treatment arm will be equally divided into two cohorts,&#xD;
      &quot;young;&quot; age 18-40 and &quot;old;&quot; age 65-85 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to manufacturing problems the transdermal patch was not produced.&#xD;
  </why_stopped>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25(OH)D</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum 25 OHD</measure>
    <time_frame>Change from baseline at 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum 25(OH)D</measure>
    <time_frame>Change from baseline at 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin Erythema</measure>
    <time_frame>For Pilot up to 30 days, For Efficacy up to 4 months, and For non-inferiority up to 6 months</time_frame>
    <description>Evaluate safety and skin tolerability of the D3forME topical supplement patch.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body Fat</measure>
    <time_frame>During only the 2 and 3 phases, only at baseline visit.</time_frame>
    <description>As an exploratory endpoint, the potential effect of body fat on response to daily D3forME topical supplement patches will be evaluated using DXA to measure body composition in the efficacy and non-inferiority studies.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>For Pilot up to 30 days, For Efficacy up to 4 months, and For non-inferiority up to 6 months</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Daily 4000IU transdermal D patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Only in the stage 2, Efficacy Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily placebo patch plus oral placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only in the stage 3, non-inferiority Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily placebo patch plus oral vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only in the stage 3 Non-inferiority Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily 4000IU topical patch plus oral placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only for the 3rd Stage of the study, Non-inferiority Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily transdermal placebo patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Only in the stage 2, Efficacy Study</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Transdermal D Patch</intervention_name>
    <arm_group_label>Daily 4000IU topical patch plus oral placebo</arm_group_label>
    <arm_group_label>Daily 4000IU transdermal D patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral vitamin D3</intervention_name>
    <arm_group_label>Daily placebo patch plus oral vitamin D</arm_group_label>
    <other_name>Obtained from Tischon corporation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <arm_group_label>Daily placebo patch plus oral placebo</arm_group_label>
    <arm_group_label>Daily placebo patch plus oral vitamin D</arm_group_label>
    <arm_group_label>Daily transdermal placebo patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <arm_group_label>Daily 4000IU topical patch plus oral placebo</arm_group_label>
    <arm_group_label>Daily placebo patch plus oral placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, community-dwelling ambulatory adults&#xD;
&#xD;
          -  Able and willing to sign informed consent&#xD;
&#xD;
          -  Age 18 to 75 years&#xD;
&#xD;
          -  Baseline serum 25OHD concentration &gt; 10 ng/mL and &lt; 50 ng/mL&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Willing to not alter the amount of their baseline vitamin D supplementation during the&#xD;
             course of this study&#xD;
&#xD;
          -  Willing to utilize sunscreen of SPF-15 or higher when sun exposure for more than 15&#xD;
             minutes is expected&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current hypercalcemia (serum calcium &gt; 10.5 mg/dl) or untreated primary&#xD;
             hyperparathyroidism&#xD;
&#xD;
          -  History of nephrolithiasis&#xD;
&#xD;
          -  Baseline 24-hour urine calcium &gt; 250 mg (female) or 300 mg (male)&#xD;
&#xD;
          -  Known risk factors for hypercalcemia, e.g., malignancy, tuberculosis, sarcoidosis&#xD;
&#xD;
          -  History of any form of cancer within the past five years with the exception of&#xD;
             adequately treated squamous cell or basal cell skin carcinoma&#xD;
&#xD;
          -  Renal failure; defined as a calculated creatinine clearance (using the Cockroft-Gault&#xD;
             approach) of ≤ 35 ml/minute&#xD;
&#xD;
          -  Severe end-organ disease, e.g., cardiovascular, hepatic, hematologic, pulmonary, etc.,&#xD;
             which might limit the ability to complete this study&#xD;
&#xD;
          -  Treatment with any drug known to interfere with vitamin D metabolism, e.g., phenytoin,&#xD;
             phenobarbital&#xD;
&#xD;
          -  Known cutaneous sensitivity/allergy to tape or adhesives&#xD;
&#xD;
          -  Known skin diseases, e.g., psoriasis, pemphigus, etc, which might alter transdermal&#xD;
             vitamin D absorption&#xD;
&#xD;
          -  Treatment with high dose vitamin D (≥ 50,000 IU weekly) or any active metabolites of&#xD;
             vitamin D, e.g., calcitriol, within six months of screening&#xD;
&#xD;
          -  Use of tanning beds or salons or unwillingness to utilize sunscreen during periods of&#xD;
             sun exposure of 15 minutes or longer&#xD;
&#xD;
          -  Planned trips/vacations likely to be associated with substantial amounts of sun&#xD;
             exposure during the course of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Binkley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Osteoporosis Clinical Research Program</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>October 31, 2018</last_update_submitted>
  <last_update_submitted_qc>October 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholecalciferol</keyword>
  <keyword>Transdermal patch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

